Richard Frank, MD, MHSA, Chief Medical Officer at Vida Health, spoke to Medical News Today about how orforglipron may expand access to GLP-1s: The choice between a pill and an injectable comes down to patient preference and potency. The injectables are clearly more potent but require a weekly injection
At Gutwell, maintenance planning often includes: Body composition review Metabolic assessment Nutrition correction Dose taper guidance if needed Relapse prevention strategy This doctor-led model helps patients stay accountable and make adjustments before weight regain becomes significant
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Moreover, it interacts with the dopaminergic and alpha-adrenergic systems to help heal gastrointestinal problems
CONFLICT OF INTEREST STATEMENT GAS has received speaking or consultancy fees from Astra Zeneca, EliLilly and Novo Nordisk, outside the submitted work